To determine the preclinical efficacy of AURKB inhibition in suppressing the emergence of cisplatin-tolerant persister HNSCC cells, we used an in vivo mouse tumor xenograft model and treated it with a combination of cisplatin and barasertib. This evidence concerns the gene AURKB and head and neck squamous cell carcinoma.